- Epizyme has been on my watch list for over a year now due to the company’s flagship product, TAZVERIK. Unfortunately, the company launched TAZVERIK right into strong COVID-19 headwinds.
- The company's earnings have been lackluster and the share price continues to hit new 52-week lows. Epizyme has responded with a number of actions that intend to improve adoption.
- I am looking to finally dip my toe in on EPZM during this recent small-cap healthcare sell-off in anticipation the company will eventually achieve their clinical and commercial goals.
- I discuss my bull thesis and will reveal my plans for establishing a pilot position in the near term.
For further details see:
Epizyme: Taking Advantage Of Recent Sell-Off